TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.45
-0.07 (-0.82%)
Apr 28, 2026, 4:00 PM EDT - Market closed

TransCode Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
8623624
Market Cap Growth
-12.99%157.88%-16.14%-51.08%-75.07%-
Enterprise Value
-10.07129.99-3.380.170.952.92
Last Close Price
8.456.8366.084264.96348237.001397090.00
PE Ratio
--0.13-0.05-0.04-0.35-1866.67
PB Ratio
0.750.61-1.201.761.831.16
P/TBV Ratio
0.560.46-0.410.501.891.20
P/FCF Ratio
--0.32-0.18-0.16-0.37-4.30
P/OCF Ratio
--0.32-0.18-0.16-0.38-4.51
EV/EBITDA Ratio
--4.660.22-0.01-0.05-0.48
EV/EBIT Ratio
--4.650.22-0.01-0.05-0.48
EV/FCF Ratio
--6.660.25-0.01-0.06-0.53
Debt / Equity Ratio
-000.0200
Debt / EBITDA Ratio
--0.00-0.02--
Debt / FCF Ratio
--0.00-0.02--
Net Debt / Equity Ratio
-1.72-1.722.86-1.41-1.53-1.02
Net Debt / EBITDA Ratio
0.640.640.380.120.273.41
Net Debt / FCF Ratio
0.910.910.430.130.313.77
Quick Ratio
5.375.372.100.791.238.22
Current Ratio
6.296.292.561.281.708.97
Return on Equity (ROE)
-45.96%-46.26%8866.94%-759.85%-148.57%-80.53%
Return on Assets (ROA)
-32.76%-32.76%-251.29%-304.42%-122.08%-51.27%
Return on Invested Capital (ROIC)
-39.75%-39.75%1671.49%1633.95%1758.98%2308.94%
Return on Capital Employed (ROCE)
-34.24%-34.24%-505.04%-789.40%-157.61%-58.43%
Earnings Yield
-468.11%-769.99%-2022.75%-2244.62%-287.30%-0.05%
FCF Yield
-251.96%-311.72%-550.01%-625.37%-267.96%-23.25%
Buyback Yield / Dilution
-5392.22%-5392.22%-6382.75%-1003.39%0.00%-179.92%
Total Shareholder Return
-5392.22%-5392.22%-6382.75%-1003.39%0.00%-179.92%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q